Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.03
GNC's Cash-to-Debt is ranked lower than
95% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.51 vs. GNC: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
GNC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.1 Max: 0.31
Current: 0.03
0.02
0.31
Equity-to-Asset -0.03
GNC's Equity-to-Asset is ranked lower than
98% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. GNC: -0.03 )
Ranked among companies with meaningful Equity-to-Asset only.
GNC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.05  Med: 0.28 Max: 0.42
Current: -0.03
-0.05
0.42
Debt-to-Equity -29.48
GNC's Debt-to-Equity is ranked lower than
99.99% of the 301 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.52 vs. GNC: -29.48 )
Ranked among companies with meaningful Debt-to-Equity only.
GNC' s Debt-to-Equity Range Over the Past 10 Years
Min: -29.48  Med: 1.66 Max: 5.32
Current: -29.48
-29.48
5.32
Debt-to-EBITDA -6.65
GNC's Debt-to-EBITDA is ranked lower than
99.99% of the 296 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.38 vs. GNC: -6.65 )
Ranked among companies with meaningful Debt-to-EBITDA only.
GNC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -13.65  Med: 2.99 Max: 5.09
Current: -6.65
-13.65
5.09
Piotroski F-Score: 3
Altman Z-Score: 1.74
Beneish M-Score: -3.96
WACC vs ROIC
4.14%
-19.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -11.67
GNC's Operating Margin % is ranked lower than
94% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. GNC: -11.67 )
Ranked among companies with meaningful Operating Margin % only.
GNC' s Operating Margin % Range Over the Past 10 Years
Min: -11.67  Med: 13.63 Max: 17.62
Current: -11.67
-11.67
17.62
Net Margin % -14.56
GNC's Net Margin % is ranked lower than
94% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.98 vs. GNC: -14.56 )
Ranked among companies with meaningful Net Margin % only.
GNC' s Net Margin % Range Over the Past 10 Years
Min: -14.56  Med: 6.39 Max: 10.09
Current: -14.56
-14.56
10.09
ROE % -386.03
GNC's ROE % is ranked lower than
99% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.10 vs. GNC: -386.03 )
Ranked among companies with meaningful ROE % only.
GNC' s ROE % Range Over the Past 10 Years
Min: -386.03  Med: 15.97 Max: 35.82
Current: -386.03
-386.03
35.82
ROA % -15.96
GNC's ROA % is ranked lower than
95% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.68 vs. GNC: -15.96 )
Ranked among companies with meaningful ROA % only.
GNC' s ROA % Range Over the Past 10 Years
Min: -15.96  Med: 5.45 Max: 10.02
Current: -15.96
-15.96
10.02
ROC (Joel Greenblatt) % -41.11
GNC's ROC (Joel Greenblatt) % is ranked lower than
95% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.54 vs. GNC: -41.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -41.11  Med: 48.25 Max: 72.54
Current: -41.11
-41.11
72.54
3-Year Revenue Growth Rate 10.70
GNC's 3-Year Revenue Growth Rate is ranked higher than
75% of the 346 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.90 vs. GNC: 10.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GNC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.15 Max: 13.2
Current: 10.7
0
13.2
GuruFocus has detected 4 Warning Signs with GNC Holdings Inc GNC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNC's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GNC Guru Trades in Q3 2016

Paul Tudor Jones 18,790 sh (New)
Steven Cohen 294,800 sh (New)
Chuck Royce 50,102 sh (New)
Ray Dalio 21,261 sh (New)
Jim Simons 162,900 sh (New)
Mario Gabelli 44,300 sh (+30.29%)
Private Capital Sold Out
Joel Greenblatt Sold Out
John Burbank Sold Out
» More
Q4 2016

GNC Guru Trades in Q4 2016

Jim Simons 756,100 sh (+364.15%)
Chuck Royce 133,238 sh (+165.93%)
Mario Gabelli 93,300 sh (+110.61%)
Paul Tudor Jones 20,800 sh (+10.70%)
Ray Dalio Sold Out
Steven Cohen Sold Out
» More
Q1 2017

GNC Guru Trades in Q1 2017

Chuck Royce 179,235 sh (+34.52%)
Paul Tudor Jones 27,000 sh (+29.81%)
Mario Gabelli 105,000 sh (+12.54%)
Jim Simons 466,895 sh (-38.25%)
» More
Q2 2017

GNC Guru Trades in Q2 2017

Lee Ainslie 331,740 sh (New)
Mario Gabelli 115,000 sh (+9.52%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 122 sh (-99.93%)
» More
» Details

Insider Trades

Latest Guru Trades with GNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Add 9.52%$6.65 - $9.2 $ 8.108%115,000
Mario Gabelli 2017-03-31 Add 12.54%$6.95 - $11.45 $ 8.10-6%105,000
Mario Gabelli 2016-12-31 Add 110.61%0.01%$10.84 - $21.68 $ 8.10-48%93,300
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446199    SIC: 5912
Compare:IST:SELEC, XSWX:ROSE, SHSE:600833, TSE:2772, SZSE:002788, TSE:2664, TSE:3385, NAS:PETS, OHEL:OKDBV, HKSE:01345, MEX:BEVIDES B, SZSE:002758, MIC:APTK, WAR:NEU, XKLS:7668, NZSE:GXH, MIC:PRTK, BSP:BPHA3, HKSE:03332, TSE:8095 » details
Traded in other countries:IGN.Germany,
Headquarter Location:USA
GNC Holdings Inc is a health and wellness products retailer. Its product offering includes health and wellness products such as vitamins, herbal supplements, sports nutrition products, and diet products.

GNC Holdings is a specialty retailer of health and wellness products that include vitamins, herbal supplements, sports nutrition products, and diet products. The company sells a broad range of nutritional products, including proprietary and third-party brands through three segments: retail, franchise, and manufacturing/wholesale (third party). Most of GNC's revenue is derived through the retail segment, where traditional shopping mall and strip shopping center locations generate a large percentage of the segment's sales.

Top Ranked Articles about GNC Holdings Inc

Technical Insights on Services Stocks -- Walgreens Boots Alliance, GNC Holdings, Rite Aid, and AmerisourceBergen
GNC Holdings, Inc. Third Quarter 2017 Earnings Release, Webcast and Conference Call Scheduled for October 26, 2017
GNC Grants CEO Ken Martindale Inducement Awards Pursuant To NYSE Rule 303A.08
GNC Names Ken Martindale Permanent CEO
The GNC Live Well Foundation, along with GNC customers and Associates donated $276,575 to the USATF Foundation.
GNC Holdings, Inc. Second Quarter 2017 Earnings Release, Webcast and Conference Call Scheduled for July 27, 2017
GNC Live Well Foundation Donates to Pittsburgh's Midtown Towers Fire Victims
Chuck Royce Continues to Buy These 10 Stocks Guru increased these holdings in the last 2 quarters
Chuck Royce (Trades, Portfolio) manages a portfolio composed of 1,116 stocks with a total value of $15.292 billion. In both the first quarter of 2017 and fourth-quarter 2016 the guru bought shares in the following stocks. Read more...
Mario Gabelli Continues to Buy These 9 Stocks Guru increased these holdings in the last 2 quarters
Mario Gabelli (Trades, Portfolio) is the founder, chairman and CEO of Gabelli Asset Management Co. Investors (GAMCO), a $30 billion global investment firm. In both the first quarter of 2017 and fourth-quarter 2016 the guru bought shares in the following stocks. Read more...
GNC Holdings, Inc. First Quarter 2017 Earnings Release, Webcast and Conference Call Scheduled for April 18, 2017

Ratios

vs
industry
vs
history
Forward PE Ratio 5.23
GNC's Forward PE Ratio is ranked higher than
97% of the 65 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.08 vs. GNC: 5.23 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PS Ratio 0.23
GNC's PS Ratio is ranked higher than
70% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. GNC: 0.23 )
Ranked among companies with meaningful PS Ratio only.
GNC' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.41 Max: 2.3
Current: 0.23
0.18
2.3
Price-to-Free-Cash-Flow 6.10
GNC's Price-to-Free-Cash-Flow is ranked higher than
90% of the 159 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.63 vs. GNC: 6.10 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GNC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.74  Med: 17.6 Max: 34.58
Current: 6.1
3.74
34.58
Price-to-Operating-Cash-Flow 3.70
GNC's Price-to-Operating-Cash-Flow is ranked higher than
84% of the 198 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.46 vs. GNC: 3.70 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GNC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.63  Med: 13.54 Max: 25.35
Current: 3.7
2.63
25.35
EV-to-EBIT -6.96
GNC's EV-to-EBIT is ranked lower than
99.99% of the 316 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.23 vs. GNC: -6.96 )
Ranked among companies with meaningful EV-to-EBIT only.
GNC' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.4  Med: 11.8 Max: 16.9
Current: -6.96
-14.4
16.9
EV-to-EBITDA -8.86
GNC's EV-to-EBITDA is ranked lower than
99.99% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.89 vs. GNC: -8.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22  Med: 10.4 Max: 14.3
Current: -8.86
-22
14.3
EV-to-Revenue 0.82
GNC's EV-to-Revenue is ranked lower than
66% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.60 vs. GNC: 0.82 )
Ranked among companies with meaningful EV-to-Revenue only.
GNC' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 1.8 Max: 2.6
Current: 0.82
0.8
2.6
Current Ratio 3.21
GNC's Current Ratio is ranked higher than
91% of the 358 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.18 vs. GNC: 3.21 )
Ranked among companies with meaningful Current Ratio only.
GNC' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.06 Max: 3.91
Current: 3.21
2.21
3.91
Quick Ratio 0.84
GNC's Quick Ratio is ranked higher than
58% of the 358 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.74 vs. GNC: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
GNC' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.2 Max: 1.85
Current: 0.84
0.64
1.85
Days Inventory 130.29
GNC's Days Inventory is ranked lower than
94% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.32 vs. GNC: 130.29 )
Ranked among companies with meaningful Days Inventory only.
GNC' s Days Inventory Range Over the Past 10 Years
Min: 111.41  Med: 120.01 Max: 130.29
Current: 130.29
111.41
130.29
Days Sales Outstanding 16.87
GNC's Days Sales Outstanding is ranked lower than
55% of the 281 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.08 vs. GNC: 16.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.87  Med: 19.49 Max: 20.17
Current: 16.87
16.87
20.17
Days Payable 29.74
GNC's Days Payable is ranked lower than
71% of the 273 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 42.45 vs. GNC: 29.74 )
Ranked among companies with meaningful Days Payable only.
GNC' s Days Payable Range Over the Past 10 Years
Min: 28.13  Med: 31.35 Max: 41.66
Current: 29.74
28.13
41.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.92
GNC's Dividend Yield % is ranked higher than
91% of the 492 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.98 vs. GNC: 4.92 )
Ranked among companies with meaningful Dividend Yield % only.
GNC' s Dividend Yield % Range Over the Past 10 Years
Min: 0.27  Med: 1.49 Max: 10.47
Current: 4.92
0.27
10.47
3-Year Dividend Growth Rate 10.10
GNC's 3-Year Dividend Growth Rate is ranked higher than
54% of the 189 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.20 vs. GNC: 10.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GNC' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 17.8
Current: 10.1
0
17.8
5-Year Yield-on-Cost % 4.79
GNC's 5-Year Yield-on-Cost % is ranked higher than
71% of the 516 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.05 vs. GNC: 4.79 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GNC' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.27  Med: 1.49 Max: 10.47
Current: 4.79
0.27
10.47
3-Year Average Share Buyback Ratio 10.10
GNC's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 220 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. GNC: 10.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.1  Med: 7 Max: 0
Current: 10.1
-4.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.24
GNC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 225 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.39 vs. GNC: 0.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GNC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.22  Med: 0.62 Max: 2.01
Current: 0.24
0.22
2.01
Price-to-Median-PS-Value 0.16
GNC's Price-to-Median-PS-Value is ranked higher than
98% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. GNC: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.02 Max: 1.54
Current: 0.16
0.14
1.54
Price-to-Peter-Lynch-Fair-Value 0.25
GNC's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 110 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.68 vs. GNC: 0.25 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GNC' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.73 Max: 0.89
Current: 0.25
0
0.89
Earnings Yield (Greenblatt) % -14.38
GNC's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.84 vs. GNC: -14.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.7  Med: 8 Max: 14.9
Current: -14.38
-14.7
14.9
Forward Rate of Return (Yacktman) % 40.58
GNC's Forward Rate of Return (Yacktman) % is ranked higher than
94% of the 252 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.34 vs. GNC: 40.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GNC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 21.7  Med: 24.2 Max: 40.58
Current: 40.58
21.7
40.58

More Statistics

Revenue (TTM) (Mil) $2,483.73
EPS (TTM) $ -5.18
Beta0.46
Short Percentage of Float38.57%
52-Week Range $6.51 - 22.32
Shares Outstanding (Mil)68.47

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 2,522 2,567 2,622 2,706
EPS ($) 1.54 1.60 1.75 2.05
EPS without NRI ($) 1.54 1.60 1.75 2.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-1.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}